PDCD1 and non-small cell lung carcinoma: Therefore, among the 96 NSCLC patients receiving combination of anti-angiogenic and anti-PD-1 therapy in Wuhan University People's Hospital from January 2018 to December 2021, only 14 specimens met the study requirements.